Phase 2b Trial for Mitochondrial Diseases has Begun
source: pixabay.com

Phase 2b Trial for Mitochondrial Diseases has Begun

Khondrion has just announced that the very first patient has been dosed in their Phase 2b study for mitochondrial diseases called KHENERGYZE. This patient population has a high unmet need…

Continue Reading Phase 2b Trial for Mitochondrial Diseases has Begun
ICYMI: The Affordable Care Act May be Ruled Unconstitutional: Patient Groups Unite to Ask for a Prompt Decision
source: pixabay.com

ICYMI: The Affordable Care Act May be Ruled Unconstitutional: Patient Groups Unite to Ask for a Prompt Decision

As originally reported in NewsRoom, the US's political volatility over the past years has thrown many policies and legislation into debate. While switching the party in both the executive and…

Continue Reading ICYMI: The Affordable Care Act May be Ruled Unconstitutional: Patient Groups Unite to Ask for a Prompt Decision
This Glomerulonephritis Patient has Been Receiving Dialysis Treatment for Over 30 Years. Now he Shares his Discipline with Other Patients
source: pixabay.com

This Glomerulonephritis Patient has Been Receiving Dialysis Treatment for Over 30 Years. Now he Shares his Discipline with Other Patients

  According to a recent article in the MalayMail, it occurred to Abdullah’s doctor that the 67-year-old would be an inspiration for others who have kidney failure. His nephrologist, Dr.…

Continue Reading This Glomerulonephritis Patient has Been Receiving Dialysis Treatment for Over 30 Years. Now he Shares his Discipline with Other Patients
ICYMI: The Manufacturer of Spinal Muscular Atrophy Drug Zolgensma has Made a Lottery for Life
source: pixabay.com

ICYMI: The Manufacturer of Spinal Muscular Atrophy Drug Zolgensma has Made a Lottery for Life

As originally reported in Euronews, there is limited supply of expensive medicines for rare diseases, so it can be difficult to prioritize which patients will have their lives saved when…

Continue Reading ICYMI: The Manufacturer of Spinal Muscular Atrophy Drug Zolgensma has Made a Lottery for Life
India Has Introduced a New Rare Disease Policy Draft, But it Doesn’t Benefit all Rare Patients
source: pixabay.com

India Has Introduced a New Rare Disease Policy Draft, But it Doesn’t Benefit all Rare Patients

India first drafted a national rare disease policy back in 2017. Unfortunately, it was never enacted due to budgeting and implementation issues. This draft included suggestions such as a corpus…

Continue Reading India Has Introduced a New Rare Disease Policy Draft, But it Doesn’t Benefit all Rare Patients
A 1,000 Patient Trial for Acute Lymphoblastic Leukemia and Other Hematologic Malignancies is Now Enrolling
source: pixabay.com

A 1,000 Patient Trial for Acute Lymphoblastic Leukemia and Other Hematologic Malignancies is Now Enrolling

The Platform Notable's automated technology platform was created to help predict which patients would respond better to which therapies. As no patient is the same, this study is paramount. Notable…

Continue Reading A 1,000 Patient Trial for Acute Lymphoblastic Leukemia and Other Hematologic Malignancies is Now Enrolling
Searching for the Cause of Lung Disease in Systemic Juvenile Idiopathic Arthritis
source: pixabay.com

Searching for the Cause of Lung Disease in Systemic Juvenile Idiopathic Arthritis

  According to a recent article in MedPage Today’s 2019 year-end review, the number of life-threatening lung diseases in systemic juvenile idiopathic arthritis (sJIA) patients has been increasing. sJIA is…

Continue Reading Searching for the Cause of Lung Disease in Systemic Juvenile Idiopathic Arthritis
Acromegaly Community to Host Patient-Focused Drug Development Meeting with FDA
source: pixabay.com

Acromegaly Community to Host Patient-Focused Drug Development Meeting with FDA

On April 28th, 2020, Acromegaly Community, a nonprofit organization that is dedicated to supporting acromegaly patients, will be hosting a patient focused drug development meeting (PFDD). These meetings are an…

Continue Reading Acromegaly Community to Host Patient-Focused Drug Development Meeting with FDA